YTYeganeh Talebkhan

Yeganeh Talebkhan

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Yeganeh Talebkhan has a total of 105 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Development of a flow cytometric immunoassay using recombinant vascular endothelial growth factor (VEGF)-functionalized poly(ε-caprolactone) microbeads for bevacizumab quantification

    by Negar Namaei-Ghasemnia, Mohammad Rabiee, Fatemeh Davami, Yeganeh Talebkhan-Garoosi, Mohamad Ghorbani

    Purpose: With the growing research interest in therapeutic monoclonal antibodies (mAbs) and their broad range of applications, the development of reliable analytical approaches for their quantification has become increasingly important. Since, microbead (MB)-based flow cytometric immunoassays have emerged as highly sensitive analytical methods, the aim of this study was to develop and evaluate a flow cytometry-based method using poly(ε-caprolactone) (PCL) MBs to quantify bevacizumab (BVZ) concentration. Methods: PCL MBs were synthesized through the emulsion/solvent evaporation method and modified by reaction with 1,2-ethylenediamine (EDA) to enable covalent binding of biomolecules. Based on the optimal biomolecule immobilization conditions determined using a model protein, purified recombinant vascular endothelial growth factor (VEGF) protein was immobilized on the surface of amine-functionalized MBs (A-MBs(45)) to capture BVZ, which was then detected using fluorescein isothiocyanate (FITC)-conjugated anti-human IgG antibody in flow cytometry. Results: The synthesized PCL MBs, with an average diameter of 6.62 ± 0.17 µm, were within the suitable particle size range for immunoassay applications. The optimal aminolysis time was found to be 45 min at 37 °C, and the maximum protein coupling was achieved 5 h post-incubation at pH 8.0. The developed MB-based flow cytometric immunoassay demonstrated the potential to quantify BVZ with a limit of detection (LOD) and limit of quantification (LOQ) of about 6.71 and 22.73 ng mL-1, respectively. Conclusion: Considering the ease of fabrication and functionalization of PCL MBs under the obtained optimal conditions, along with their capability for analyte detection, these cost-effective analytical platforms may serve as promising candidates for BVZ quantification.

  • Cetuximab scFv-modified 5-FU Loaded Chitosan Nanoparticles: A Novel Therapeutic Platform

    by Masumeh Jalalvand, Fariba Esmaeili, Khadijeh Falahzadeh, Mohammadali Mazloumi, Gholamreza Shahsavari, Elham Bayat, Farshid Zandsalimi, Yeganeh Talebkhan, Leila Nematollahi, Babak Negahdari

    Background: Colorectal cancer [CRC] is among the most fatal types of cancer. An active targeting delivery system that specifically interacts with CRC cells could improve the therapy's outcomes. Herein, Cetuximab single-chain fragment variable antibody [scFv] fragments were conjugated to the surface of 5-FU encapsulated chitosan nanoparticles [CS NPs] to develop an effective therapeutic platform [scFv-CS/5-FU NPs]. Methods: CS/5-FU NPs were synthesized using a special fluidic system. Encapsulation efficiency [EE], loading capacity [LC], and the drug release profile of the particles were determined. scFv fragments were produced recombinantly and tailored on the surface of CS/5-FU NPs. The physicochemical features of scFv-CS/5-FU NPs were also characterized. MTT and flow cytometry assay investigated the toxicity effect of scFv-CS/5-FU NPs on the HCT116 cell line. Results: CS/5-FU NPs had a homogenous spherical shape. They possessed sustainable drugrelease behavior. The produced scFv-CS/5-FU NPs were also spherical. scFv-CS/5-FU NPs significantly decreased the viability of cancerous cells in a dose-dependent manner and induced apoptosis in 97.97% of targeted cells. Conclusion: scFv-CS/5-FU NPs showed remarkable anti-CRC activity. This novel targeting delivery system reduced the effective dose of 5-FU which is of vital importance to decrease the devastating side effects of chemotherapy.


  • Open Access

    A novel bispecific antibody targeting TNF-α and IL-6 receptor as a potent immunotherapeutic agent for inflammation

    by Mansooreh Heravi, Shadi Damough, Ladan Mafakher, Yeganeh Talebkhan, Leila Nematollahi, Leila Ghazizadeh, Soheila Ajdari

    Tumor necrosis factor-alpha and interleukin-6 are proinflammatory cytokines involved in several autoimmune diseases, including rheumatoid arthritis. Althou


  • Open Access

    Helicobacter pylori Dihydroorotate Dehydrogenase: a Promising Target for Screening Potential Drug Candidates

    by Saba Ghaffari, Maryam Esmaeili, Fatemeh Ayoubnejad, Yeganeh Talebkhan, Marjan Mohammadi

    Background: De novo pyrimidine biosynthesis is essential for the survival of all living organisms. DHODH catalyzes the fourth step in this pathway. Inhibition of DHODH induces pyrimidine depletion and effectively eradicates microorganisms like H. pylori, which lacks the pyrimidine salvage pathway. Herein, we expressed rHp-DHODH, characterized its enzymatic activity, kinetics, ...


  • Open Access

    Development of Experimental Platforms to Assess Helicobacter pylori HopQ Interaction with Host CEACAM Molecules

    by Nazanin Shans, Maryam Esmaeili, Kimia Abraheh, Niloofar Asadi Hanjani, Maedeh Farrokhi, Negar Sardarpour, Yeganeh Talebkhan, Fatemeh Kazemi-Lomedasht, Esmat Mirabzadeh, Marjan Mohammadi

    Background: Helicobacter pylori is an extracellular bacterium responsible for various gastrointestinal diseases, such as peptic ulcers and gastric cancer. It uses multiple mechanisms to colonize the harsh, acidic environment of the stomach and establish its pathogenic processes, mostly through CagA translocation. While cell surface integrin molecules were previously believed to ...


  • Open Access

    Optimization of Culture Conditions to Improve Follicle-Stimulating Hormone Production by CHO-DG44 Cells in Serum-Free Medium

    by Hanna Ghobadian, Khashayar Roshanzamir, Mohammadhasan Kouhi Abdolabadi, Hadi Ostadi, Reza Zati Keikha, Mohammad Dolatkhah Baghan, Yeganeh Talebkhan, Fatemeh Torkashvand

    Background: In the present study, we attempted to adapt an adherent and serum-dependent Chinese hamster ovary DG44 cell line to a serum-free suspension culture and optimize the culture condition to achieve a higher yield of recombinant human follicle stimulating hormone (r-hFSH) with acceptable quality. This approach helps to mitigate the risks associated ...


  • Open Access

    Optimization of culture condition for Spodoptera frugiperda by design of experiment approach and evaluation of its effect on the expression of hemagglutinin protein of influenza virus

    by Fatemeh Alizadeh, Hamideh Aghajani, Fereidoun Mahboudi, Yeganeh Talebkhan, Ehsan Arefian, Sepideh Samavat, Rouhollah Raufi

    The baculovirus expression vector system (BEVS) is a powerful tool in pharmaceutical biotechnology to infect insect cells and produce the recombinant proteins of interest. It has been well documented that optimizing the culture condition and its supplementation through designed experiments is critical for maximum protein production. In this study, besides physicochemical parameters including incubation temperature, cell count of infection, multiplicity of infection, and feeding percentage, potential supplementary factors such as cholesterol, polyamine, galactose, pluronic-F68, glucose, L-glutamine, and ZnSO4 were screened for Spodoptera frugiperda (Sf9) cell culture and expression of hemagglutinin (HA) protein of Influenza virus via Placket-Burman design and then optimized through Box-Behnken approach. The optimized conditions were then applied for scale-up culture and the expressed r-HA protein was characterized. Optimization of selected parameters via the Box-Behnken approach indicated that feed percentage, cell count, and multiplicity of infection are the main parameters affecting r-HA expression level and potency compared to the previously established culture condition. This study demonstrated the effectiveness of designing experiments to select and optimize important parameters that potentially affect Sf9 cell culture, r-HA expression, and its potency in the BEVS system.


    • 29 May 2024
      • Vol. 28  (5 & 6) , 282-96
    Open Access

    Optimization of Culture Conditions to Improve Follicle-Stimulating Hormone Production by CHO-DG44 Cells in Serum-Free Medium.

    by Hanna Ghobadian, Khashayar Roshanzamir, Mohammadhasan Kouhi Abdolabadi, Hadi Ostadi, Reza Zati Keikha, Mohammad Dolatkhah Baghan, Yeganeh Talebkhan, Fatemeh Torkashvand

    In the present study, we attempted to adapt an adherent and serum-dependent Chinese hamster ovary DG44 cell line to a serum-free suspension culture and optimize the culture condition to achieve a higher yield of r-hFSH with acceptable quality. This approach helps to mitigate the risks associated with blood-borne pathogens, reduces lot-to-lot variability, and lowers costs, making it suitable for industrial processing and scale-up. The cell adaptation was performed using different chemically defined SFM. This process was followed by optimization through statistical experimental design, focusing on selected physicochemical parameters, including chemical supplementation of the medium and temperature shift. Both small- and large-scale cultures were conducted to test the reproducibility of the optimized condition. The expressed protein was evaluated for comparability with the standard molecule according to the Pharmacopeia guidelines. RSM analysis indicated that supplementation of the culture medium with galactose and NaBu, along with a temperature downshift, were the main parameters leading to increased cell viability (10%), r-hFSH level (96%), and more importantly, the glycosylation content (49%) of r-hFSH compared to the control condition. As r-hFSH isoforms generated during in vivo post-translational modifications typically exhibit different serum/plasma half-lives and bioactivity due to their incorporated sialic acid content/glycosylation, further optimizations of r-hFSH production are necessary to enhance its biological activity. In this study, following a primary screening of the studied parameters, optimization of culture conditions based on selected parameters resulted in enhanced quality and quantity of the produced r-hFSH. However, further examination is necessary before transitioning to industrial production.


  • Open Access

    A novel nanobody-based immunocytokine of a mutant interleukin-2 as a potential cancer therapeutic

    by Arezoo Beig Parikhani, Rada Dehghan, Yeganeh Talebkhan, Elham Bayat, Alireza Biglari, Mohammad Ali Shokrgozar, Reza Ahangari Cohan, Esmat Mirabzadeh, Soheila Ajdary, Mahdi Behdani

    The immunotherapeutic application of interleukin-2 (IL-2) in cancer treatment is limited by its off-target effects on different cell populations and insufficient activation of anti-tumor effector cells at the site of the tumor upon tolerated doses. Targeting IL-2 to the tumor microenvironment by generating antibody-cytokine fusion proteins (immunocytokine) would be a promising approach to increase efficacy without associated toxicity. In this study, a novel nanobody-based immunocytokine is developed by the fusion of a mutant (m) IL-2 with a decreased affinity toward CD25 to an anti-vascular endothelial growth factor receptor-2 (VEGFR2) specific nanobody, denoted as VGRmIL2-IC. The antigen binding, cell proliferation, IFN-γ-secretion, and cytotoxicity of this new immunocytokine are evaluated and compared to mIL-2 alone. Furthermore, the pharmacokinetic properties are analyzed. Flow cytometry analysis shows that the VGRmIL2-IC molecule can selectively target VEGFR2-positive cells. The results reveal that the immunocytokine is comparable to mIL-2 alone in the stimulation of Primary Peripheral Blood Mononuclear Cells (PBMCs) and cytotoxicity in in vitro conditions. In vivo studies demonstrate improved pharmacokinetic properties of VGRmIL2-IC in comparison to the wild or mutant IL-2 proteins. The results presented here suggest VGRmIL2-IC could be considered a candidate for the treatment of VEGFR2-positive tumors.


  • Open Access

    Recombinant anti-human epidermal growth factor receptor type 2 single-chain variable fragment-alpha-luffin fusion protein as a putative immunotoxin against human epidermal growth factor receptor type 2-positive breast cancer cells: an experimental research

    by Shadi Msc Damough, Elham Msc Bayat, Tayebeh Msc Oghabi Bakhshaiesh, Farzaneh Barkhordari, Rezvan Esmaeili, Leila Nematollahi, Yeganeh Talebkhan

    Background: Breast cancer is one of the most frequent causes of cancer death in women. The application of immunotoxins to target overexpressed biomarkers on the surface of cancer cells and delivery of the toxin molecules into these cells has attracted too much attention during the last decade. Objectives: This study was conducted to investigate the possible in-vitro cytotoxic and apoptotic activity of previously designed recombinant immunotoxin compromising anti-HER2 single-chain variable fragment (scFv) and alpha-luffin protein in human epidermal growth factor receptor type 2 (HER2)-positive and HER2-negative breast cancer cell lines. Materials and methods: The previously designed recombinant immunotoxin and alpha-luffin protein were expressed in E. coli host cells and purified using Ni-affinity chromatography. The cytotoxicity of the proteins was tested through MTT and apoptosis studies on HER2-positive and HER2-negative breast cancer cell lines. Results: Treatment of SKBR3 and MDA-MB-468 cells with the immunotoxin caused differential cytotoxicity and apoptotic events. Flow cytometry analysis indicated that the immunotoxin could arrest SKBR3 cells at the G0/G1 phase and induce apoptosis and cell death which were not observed in HER2-negative MDA-MB-468 cells. Annexin V/PI staining revealed late apoptotic events in SKBR3 cells treated with the immunotoxin which was different from the early apoptosis induced by the alpha-luffin protein alone. Conclusions: This immunotoxin could be a promising tool in developing new targeted therapeutic agents against HER2-positive cancer cells. Animal experiments are needed before making firmed conclusions.